US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
biotech · Lymphoma, Non-Hodgkin · Systemic Lupus Erythematosus · CRBU
Caribou Biosciences
Caribou Biosciences drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Berkeley, USA HQ
2012 Founded
131 Employees
Public company Type
CRBU · NYSE Ticker
Company details
- Status
- Public
- HQ
- Berkeley, USA
- Founded
- 2012
- Employees
- 131
- Programs
- 4
- Drugs
- 2
- Patents
- 19
Caribou Biosciences pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Caribou Biosciences drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Caribou Biosciences in public FDA and regional records.